Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress Lead Investing
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights Lead Investing
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Lead Investing
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference Lead Investing
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update Lead Investing
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference Lead Investing
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Lead Investing
Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease Lead Investing
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024 Lead Investing
OpRegen® Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit Lead Investing
